BioCentury
ARTICLE | Clinical News

Tolenix: Additional Phase II data

March 25, 2013 7:00 AM UTC

Additional data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix (2 mg tolterodine plus 9 mg pilocarpine) led to a 0.88 reduction in daily u...